CTRI/2023/10/059253尚未招募4 期
Clinical efficacy and safety of Fluticasone furoate with cetrizine vs Fluticasone furoate with montelukast in patients with allergic rhinitis - A Randomized open label controlled trial
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Willing to sign informed consent form.
- •Patients suffering from Allergic Rhinitis.
- •Not being using Nasal steroids for past one month.
- •4 out of 12 Total Nasal Symptom Score(TNSS).
排除标准
- •Pregnancy and lactating women.
- •Known history of psychiatric illness.
- •Planned surgery of nasal cavity.
- •Patient with unknown malignancies.
研究者
相似试验
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDEUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-SEGlaxoSmithKline Research & Development Limited3,000
已完成
4 期
The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY ELLIPTA) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients within a Usual Care Setting.(study 206854)NL-OMON48721GlaxoSmithKline700